Physician
Ved V Aggarwal MD PA
Ved V Aggarwal MD PA was paid $1.15M by Medicaid between Jan 2018 and Nov 2024, across 59 billing codes. Its largest line is 99214, doctor's office visit, returning patient (more involved) — 30% of everything it billed.
33Billing provider infoVED V AGGARWAL MD PA
FORT WORTH, TX 76104
FORT WORTH, TX 76104
33aNPI1053315382assigned 06/01/2005
33bProvider typeInterventional Pain Medicine Physician
28Total paid$1.15M
24GClaims118,472
24DCodes billed59
24AFirst – last monthJan 2018 – Nov 2024
Compared with peers
Next to other Interventional Pain Medicine Physician providers in Texas
Rank by total paid#1 of 27
Median peer was paid$12K
This provider vs. median94×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 20,739 | $19K | |
| 2019 | 23,738 | $20K | |
| 2020 | 30,986 | $99K | |
| 2021 | 34,946 | $626K | |
| 2022 | 6,904 | $358K | |
| 2023 | 901 | $23K | |
| 2024incomplete | 258 | $3K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 30% | 9,765 | 9,085 | $342K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 19% | 7,701 | 7,462 | $215K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 13% | 9,931 | 9,357 | $147K |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | 12% | 817 | 781 | $137K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | 8.0% | 1,487 | 1,459 | $92K |
| 80361 | 1.8% | 1,741 | 1,701 | $20K | |
| 80323 | 1.0% | 717 | 698 | $12K | |
| 80332 | <1% | 707 | 690 | $11K | |
| 80346 | <1% | 946 | 925 | $10K | |
| 80348 | <1% | 885 | 863 | $10K | |
| 80356 | <1% | 853 | 833 | $9K | |
| 62323 | <1% | 66 | 60 | $9K |
47 more codes
| 80354 | <1% | 857 | $9K | |
| 83992 | <1% | 758 | $9K | |
| 80365 | <1% | 888 | $9K | |
| 80355 | <1% | 1,141 | $8K | |
| 80337 | <1% | 922 | $8K | |
| 80358 | <1% | 850 | $8K | |
| 80362 | <1% | 791 | $7K | |
| 80373 | <1% | 874 | $7K | |
| 80353 | <1% | 867 | $7K | |
| 80366 | <1% | 956 | $7K | |
| 80370 | <1% | 796 | $7K | |
| CP001 | <1% | 630 | $6K | |
| 80325 | <1% | 688 | $6K | |
| 80367 | <1% | 709 | $6K | |
| 80372 | <1% | 690 | $6K | |
| 80368 | <1% | 784 | $6K | |
| 80360 | <1% | 731 | $5K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 959 | $3K |
| J1040 | Injection, methylprednisolone acetate, 80 mg | <1% | 321 | $3K |
| 80324 | <1% | 137 | $1K | |
| 77002 | <1% | 38 | $921.22 | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | <1% | 26 | $607.86 |
| 84403 | <1% | 27 | $554.07 | |
| 84270 | <1% | 27 | $466.67 | |
| 82670 | <1% | 18 | $417.12 | |
| 83001 | <1% | 27 | $399.05 | |
| 83002 | <1% | 27 | $397.44 | |
| 84481 | <1% | 27 | $363.63 | |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 27 | $360.64 |
| 82533 | <1% | 27 | $349.83 | |
| 82607 | <1% | 27 | $323.61 | |
| 84439 | <1% | 27 | $193.66 | |
| 20610 | <1% | 25 | $139.42 | |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | <1% | 29 | $116.47 |
| G9577 | Patients prescribed opiates for longer than six weeks | 0% | 7,823 | $0.00 |
| G9584 | Patient evaluated for risk of misuse of opiates by using a brief validated instrument (e.g., opioid risk tool, soapp-r) or patient interviewed at least once during opioid therapy | 0% | 7,879 | $0.00 |
| G9578 | Documentation of signed opioid treatment agreement at least once during opioid therapy | 0% | 7,852 | $0.00 |
| G9562 | Patients who had a follow-up evaluation conducted at least every three months during opioid therapy | 0% | 7,823 | $0.00 |
| G9561 | Patients prescribed opiates for longer than six weeks | 0% | 7,824 | $0.00 |
| G8730 | Pain assessment documented as positive using a standardized tool and a follow-up plan is documented | 0% | 8,309 | $0.00 |
| G8427 | Eligible clinician attests to documenting in the medical record they obtained, updated, or reviewed the patient's current medications | 0% | 9,152 | $0.00 |
| G8417 | Bmi is documented above normal parameters and a follow-up plan is documented | 0% | 2,446 | $0.00 |
| Q9966 | Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml | 0% | 47 | $0.00 |
| G9583 | Patients prescribed opiates for longer than six weeks | 0% | 7,882 | $0.00 |
| G8420 | Bmi is documented within normal parameters and no follow-up plan is required | 0% | 42 | $0.00 |
| J2704 | Injection, propofol, 10 mg | 0% | 32 | $0.00 |
| 36415 | Collection of venous blood by venipuncture | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialAGGARWAL, VED (OWNER)
| Provider | Location | Paid |
|---|---|---|
| Summit Pain & Anesthesia Consultants | Fort Worth, TX | $5K |
| Watermere Surgery Center LLC | Southlake, TX | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.